ArticleAdvanced healthcare materials2020
Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair.
Article in Advanced healthcare materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Comparative Evaluation of Decellularized Human Amniotic Membrane and Wharton's Jelly in a Rat Model of Myocardial Infarction: Experimental Study.Current issues in molecular biology · 2026Article
- Proteomic evaluation and comparison of native and decellularized human saphenous vein extracellular matrices.Frontiers in bioengineering and biotechnology · 2026Article
- Transforming Human Amniotic Membrane into Nanoparticles: An Approach for Cardiac Delivery Systems.ACS applied bio materials · 2025Article
- Preclinical extracellular matrix-based treatment strategies for myocardial infarction: a systematic review and meta-analysis.Communications medicine · 2025Article
- A pilot study for decellularizing porcine cornea for future use in corneal regeneration.PloS one · 2025Article
- Biosynthetic gas vesicles as a novel ultrasound contrast agent for diagnosing and treating myocardial infarction.Theranostics · 2025Article
- The impact of mechanical tuning on the printability of decellularized amniotic membrane bioinks for cell-laden bioprinting of soft tissue constructs.Scientific reports · 2024Article
- Amniotic membrane, a novel bioscaffold in cardiac diseases: from mechanism to applications.Frontiers in bioengineering and biotechnology · 2024Review
- Amnion-derived hydrogels as a versatile platform for regenerative therapy: from lab to market.Frontiers in bioengineering and biotechnology · 2024Review
- Biological importance of human amniotic membrane in tissue engineering and regenerative medicine.Materials today. Bio · 2023Review
- Article
- Optimization of FDM 3D printing process parameters to produce haemodialysis curcumin-loaded vascular grafts.Drug delivery and translational research · 2023Article
- Placental-Derived Biomaterials and Their Application to Wound Healing: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.Heart failure reviews · 2022Review
- Galectin-1 alleviates myocardial ischemia-reperfusion injury by reducing the inflammation and apoptosis of cardiomyocytes.Experimental and therapeutic medicine · 2022Article
- The role of adipose-derived stem cells-derived extracellular vesicles in the treatment of diabetic foot ulcer: Trends and prospects.Frontiers in endocrinology · 2022Review
- Placental Tissues as Biomaterials in Regenerative Medicine.BioMed research international · 2022Review
- Therapeutic Acellular Scaffolds for Limiting Left Ventricular Remodelling-Current Status and Future Directions.International journal of molecular sciences · 2021Review
- Bone-Marrow Stem Cells and Acellular Human Amniotic Membrane in a Rat Model of Heart Failure.Life (Basel, Switzerland) · 2021Article
- Human acellular amniotic membrane incorporating exosomes from adipose-derived mesenchymal stem cells promotes diabetic wound healing.Stem cell research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.